Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection MW Fried, ML Shiffman, KR Reddy, C Smith, G Marinos, FL Gonçales Jr, ... New England journal of medicine 347 (13), 975-982, 2002 | 8631 | 2002 |
EASL Clinical Practice Guidelines: management of hepatitis C virus infection European Association For The Study Of The Liver Journal of hepatology 55 (2), 245-264, 2011 | 2500 | 2011 |
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ... The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017 | 2101 | 2017 |
Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904, 2018 | 1613 | 2018 |
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C GL Davis, R Esteban-Mur, V Rustgi, J Hoefs, SC Gordon, C Trepo, ... New England journal of medicine 339 (21), 1493-1499, 1998 | 1587 | 1998 |
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ... The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018 | 1527 | 2018 |
Statements from the Taormina expert meeting on occult hepatitis B virus infection G Raimondo, JP Allain, MR Brunetto, MA Buendia, DS Chen, M Colombo, ... Journal of hepatology 49 (4), 652-657, 2008 | 1143 | 2008 |
Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 1117 | 2016 |
Preoperative radiotherapy for resectable rectal cancer: a meta-analysis C Cammà, M Giunta, F Fiorica, L Pagliaro, A Craxì, M Cottone Jama 284 (8), 1008-1015, 2000 | 1104 | 2000 |
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials C Camma, F Schepis, A Orlando, M Albanese, L Shahied, F Trevisani, ... Radiology 224 (1), 47-54, 2002 | 1068 | 2002 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial J Bruix, JL Raoul, M Sherman, V Mazzaferro, L Bolondi, A Craxi, PR Galle, ... Journal of hepatology 57 (4), 821-829, 2012 | 933 | 2012 |
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis F Fiorica, D Di Bona, F Schepis, A Licata, L Shahied, A Venturi, AM Falchi, ... Gut 53 (7), 925-930, 2004 | 754 | 2004 |
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis SL Friedman, V Ratziu, SA Harrison, MF Abdelmalek, GP Aithal, ... Hepatology 67 (5), 1754-1767, 2018 | 707 | 2018 |
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin P Ferenci, MW Fried, ML Shiffman, CI Smith, G Marinos, FL Gonçales Jr, ... Journal of hepatology 43 (3), 425-433, 2005 | 675 | 2005 |
The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent RM Mancina, P Dongiovanni, S Petta, P Pingitore, M Meroni, R Rametta, ... Gastroenterology 150 (5), 1219-1230. e6, 2016 | 643 | 2016 |
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised … IM Jacobson, GJ Dore, GR Foster, MW Fried, M Radu, VV Rafalsky, ... The Lancet 384 (9941), 403-413, 2014 | 633 | 2014 |
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease P Dongiovanni, S Petta, C Maglio, AL Fracanzani, R Pipitone, E Mozzi, ... Hepatology 61 (2), 506-514, 2015 | 567 | 2015 |
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C S Petta, C Cammà, C Scazzone, C Tripodo, V Di Marco, A Bono, D Cabibi, ... Hepatology 51 (4), 1158-1167, 2010 | 566 | 2010 |
Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? F Schepis, C Cammà, D Niceforo, A Magnano, S Pallio, M Cinquegrani, ... Hepatology 33 (2), 333-338, 2001 | 550 | 2001 |
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection T Pollicino, G Squadrito, G Cerenzia, I Cacciola, G Raffa, A Craxı̀, ... Gastroenterology 126 (1), 102-110, 2004 | 547 | 2004 |